Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association

Diabetes & Metabolism Journal
Seung-Hyun KoCommittee of Clinical Practice Guideline of Korean Diabetes Association

Abstract

In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

References

Mar 26, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Donald E G GriesdaleDaniel Talmor
May 21, 2010·Diabetes Care·Diana SherifaliHertzel C Gerstein
Nov 24, 2011·Diabetes & Metabolism Journal·Seung-Hyun KoUNKNOWN Committee of Clinical Practice Guidelines, Korean Diabetes Association
Jun 19, 2015·The Journal of Clinical Endocrinology and Metabolism·Simeon I TaylorKristina I Rother
Jun 25, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·E S MearnsC I Coleman
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Feb 3, 2016·European Journal of Clinical Pharmacology·Xiaoyan ZhongYilan Huang
Apr 5, 2016·Clinical and Investigative Medicine. Médecine Clinique Et Experimentale·Naghmeh ForoutanMitchell Levine
Apr 8, 2016·BMJ : British Medical Journal·Hugh McGuireUNKNOWN Guideline Development Group
Apr 22, 2016·Diabetes & Metabolism Journal·Seon Ah ChaSeung Hyun Ko
Apr 30, 2016·Diabetes & Metabolism Journal·Suk Chon, Jean François Gautier
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jul 21, 2016·JAMA : the Journal of the American Medical Association·Suetonia C PalmerGiovanni F M Strippoli
Sep 9, 2016·The Korean Journal of Internal Medicine·Kyoung Hwa Ha, Dae Jung Kim
Oct 22, 2016·Diabetes & Metabolism Journal·Jae Seung Yun, Seung Hyun Ko

❮ Previous
Next ❯

Citations

Oct 24, 2017·The Korean Journal of Internal Medicine·Byung-Wan LeeUNKNOWN Committee of Clinical Practice Guideline of Korean Diabetes Association
Dec 23, 2017·Diabetes & Metabolism Journal·Hyun Jin KimUNKNOWN Committee of Clinical Practice Guidelines of the Korean Diabetes Association
Jan 31, 2020·Korean journal of family medicine·Juyoung ShinWhan-Seok Choi
Nov 1, 2017·Diabetes & Metabolism Journal·Sang Youl RheeUNKNOWN Committee of Clinical Practice Guideline of Korean Diabetes Association
Nov 1, 2017·Diabetes & Metabolism Journal·Byung Wan LeeUNKNOWN Committee of Clinical Practice Guideline of Korean Diabetes Association
Jul 15, 2020·Diabetes & Metabolism Journal·Kyung-Soo KimYong-Wook Cho
Dec 31, 2019·Endocrinology and Metabolism·Hun Sung KimKun Ho Yoon
Aug 24, 2019·Diabetes & Metabolism Journal·Mee Kyoung KimUNKNOWN Committee of Clinical Practice Guidelines, Korean Diabetes Association
May 21, 2020·Diabetes & Metabolism Journal·Byung Wan LeeUNKNOWN Korean Diabetes Association (KDA) Fatty Liver Research Group
Dec 3, 2020·Drug Design, Development and Therapy·Hyounggyoon YooSeungHwan Lee
Feb 2, 2021·Journal of Diabetes Investigation·Hyunah KimHun-Sung Kim
Feb 2, 2022·Clinical Nursing Research·Rafael Oliveira Pitta LopesMarcos Antônio Gomes Brandão

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
pharmacotherapies

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

© 2022 Meta ULC. All rights reserved